Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bayer’s Zieler On The Power Of Real World Data, Asia Pacific Outlook

Executive Summary

Claus Zieler, senior vice president and head of commercial operations, Bayer pharmaceuticals division Asia Pacific, tells Scrip why real world data is “very powerful” as more stakeholders including physicians look beyond just randomized clinical trial data. Zieler also underscores the German multinational’s intent to give “special attention” to the fast-growing Asia Pacific region.

You may also be interested in...



In Transition? Bayer Exercises Option To Up Stake In JV With Zydus

Bayer is increasing its holding in its long-standing joint venture with Zydus Cadila in India by 25%, sparking off some speculation on the alliance’s future trajectory.

Biocon Insulin Aspart US Opportunity: 'Not Completely Lost But Not The Best Situation'

Biocon may not be able to make it to the current contracting cycle in the US for its Viatris-partnered biosimilar aspart, but all is not lost, the management indicates. The Indian firm is also buoyant about the prospects of taking its franchise of potentially interchangeable recombinant human insulin to the US.

Biocon Insulin Aspart US Opportunity: 'Not Completely Lost But Not The Best Situation'

Biocon may not be able to make it to the current contracting cycle in the US for its Viatris-partnered biosimilar aspart, but all is not lost, the management indicates. The Indian firm is also buoyant about the prospects of taking its franchise of potentially interchangeable recombinant human insulin to the US.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC097955

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel